Breakout Session C2 Christine Ho April 21, 2017
|
|
- Abigail Amanda Bond
- 6 years ago
- Views:
Transcription
1 3HP (12 dose Weekly INH and Rifapentine) Today and Tomorrow Christine S. Ho, M.D., M.P.H. CDC Division of Tuberculosis Elimination National Tuberculosis Conference TB Infection Breakout Session April 21, 2017 National Center for HIV/AIDS, Hepatitis, STD and Tuberculosis Prevention Division of Tuberculosis Elimination Financial Disclosure No financial interests to disclose 9 months of daily isoniazid Treatment Choices for LTBI 9 months of twice weekly isoniazid 6 months of daily isoniazid 4 months of daily rifampin labile 12 doses of weekly isoniazid and rifapentine up to 900 mg Isoniazid up to 900 mg Rifapentine Known as 12 dose INH RPT or 3HP DOT only 1
2 December 2011 A New Regimen is Born Sterling et al. Prevent TB study (TBTC Study 26) Multi site randomized control trial: INH RPT by DOT vs. 9H by SAT 7731 high risk persons enrolled Jun 01 Feb 08 INH RPT by DOT as effective as 9H in preventing TBhigher completion rate; less hepatotoxicity; more hypersensitivity Long term safety monitoring important CDC Recommendations: 12 dose INH RPT by DOT 12 weekly DOT doses of INH RPT an equal alternative to 9 months of daily self supervised INH for treating LTBI Use in otherwise healthy patients aged 12 years with a greater risk of developing TB Contacts Convertors Those with radiographic findings of healed TB HIV infected patients who are otherwise healthy and not taking antiretroviral medications For children aged 2 11 INH RPT can be considered on a case by case basis Vigilance for drug hypersensitivity reactions, particularly hypotension or thrombocytopenia MMWR Dec 9, 2011 Post marketing INH RPT Project Objectives Monitor for adverse events with 3 month INH RPT in nonresearch settings Track number of patients started on regimen Note if certain populations, risk factors or settings are associated with adverse effects (AE) more often Assess adherence and treatment completion Assess impact of INH RPT on programs Staffing Costs Conduct passive surveillance for TB after 2 years TB registry match Drug resistant TB 2
3 Post Marketing Surveillance Project Sites 16 sites using the regimen, 22 sites contributed to project design and forms DOT used for all sites Project period: June 2011 through December 2013 Bureau of Prisons Participated in study design Shared treatment results Participating Sites Represented Different Types of Programs State TB programs Entire state centralized programs Select counties decentralized programs County programs Health department (HD) partnered with community providers, student health clinics, correctional facilities Mandatory LTBI reporting in some sites Rifapentine access Some programs controlled access to RPT (authorization required) Some programs paid for RPT Some programs ordered and provided RPT Project Design Multiple volunteer sites implementing 3HP carry out postmarketing surveillance Modifiable data templates to record findings Core information collected by all sites Number of treatment starts Demographics Treatment reason Symptom review Treatment outcome Some sites collect additional information about patient characteristics or medical conditions 3
4 Template Forms Final Disposition: Completed INH RPT treatment Stopped INH RPT treatment Date / / Lost to follow up Died Other Adverse event Pending Completion of Alternate Regimen Recording Adverse Events Results 3,327 persons started 3HP 3,288 eligible to complete treatment 39 stopped treatment for contraindication 421 (13%) discontinued treatment 2,867 (87%) completed treatment 246 (58%) discontinued with symptoms 175 (42%) discontinued for other reasons 4
5 Results: Demographic Characteristics (n=3288) Patient Characteristics Total Number (%) No. completed 3HP (%) Sex Male 1759 (53.5) 1550 (88.1) Female 1529 (46.5) 1317 (86.1) Age (yrs.) 2 to (5.0) 155 (94.5) 18 to (31.5) 921 (89.1) 31 to (29.0) 834 ( 87.5) 45 to (28.6) 803 (85.3) (6.0) 154 (78.6) Race/ethnicity Hispanic 751 (22.8) 682 (90.8) Non Hispanic white 721 (21.9) 595 (82.5) Non Hispanic black 1195 (36.3) 1035 (86.6) Asian 540 (16.4) 481 (89.1) Other a 81 (2.5) 74 (91.4) Country of birth United States 1994 (60.6) 1699 (85.2) Foreign born 1294 (39.4) 1168 (90.3) Range of Treatment Completion Across 16 U.S. Sites, June 2011 December 2013 Treatment Completion Rate (%) * L E J A F D I N K H O P C B G M Participating Site * Proportion completing treatment among those eligible to complete at that site Number of participants at each site ranged from 14 to 1018 Completion ranged from % Discontinuation while reporting symptoms ranged from 0 16% Factors Associated with Treatment Discontinuation (n=3,288) Factor No. discontinued (%) Univariable Analysis RR (95% CI) Multivariable Analysis arr (95% CI) Male 208 (11.8) 0.85 ( ) ( ).041 Age 421 (12.8) 1.01 ( ) < ( ) <.001 Contact 70 (8.5) 0.60 ( ) < ( ).005 Corrections within past year 65 (12.6) 0.98 ( ) ( ).013 Homeless within past year 34 (18.8) 1.51 ( ) ( ).001 Student 7 (5.4) 0.41 ( ) ( ).044 Subgroup analysis for medical conditions and behavioral factors associated with Treatment discontinuation (n=2389) Current or past smoker 101 (18.9) 1.53 ( ) < ( )
6 Factor Factors Associated with Treatment Discontinuation (n=3,288) No. discontinued (%) Univariable Analysis RR (95% CI) Multivariable Analysis arr (95% CI) Male 208 (11.8) 0.85 ( ) ( ).041 Age 421 (12.8) 1.01 ( ) < ( ) <.001 Contact 70 (8.5) 0.60 ( ) < ( ).005 Corrections within past year 65 (12.6) 0.98 ( ) ( ).013 Homeless within past year 34 (18.8) 1.51 ( ) ( ).001 Student 7 (5.4) 0.41 ( ) ( ).044 Subgroup analysis for medical conditions and behavioral factors associated with Treatment discontinuation (n=2389) Current or past smoker 101 (18.9) 1.53 ( ) < ( ).002 Factor Factors Associated with Treatment Discontinuation (n=3,288) No. discontinued (%) Univariable Analysis RR (95% CI) Multivariable Analysis arr (95% CI) Male 208 (11.8) 0.85 ( ) ( ).041 Age 421 (12.8) 1.01 ( ) < ( ) <.001 Contact 70 (8.5) 0.60 ( ) < ( ).005 Corrections within past year 65 (12.6) 0.98 ( ) ( ).013 Homeless within past year 34 (18.8) 1.51 ( ) ( ).001 Student 7 (5.4) 0.41 ( ) ( ).044 Subgroup analysis for medical conditions and behavioral factors associated with Treatment discontinuation (n=2389) Current or past smoker 101 (18.9) 1.53 ( ) < ( ).002 Proportion of Patients on 3HP Who Stopped Treatment by Dose 11 doses counted as completion of therapy Y axis shows proportion of patient who had the dose as their last dose divided by total patients who received that dose 6
7 Number of patients that started 3HP reporting symptoms at least once, by treatment outcome (n=1174) % 400 5% 12% 3% 300 8% 7% 8% % 9% 3% 2% 5% 5% 6% 6% 6% 3% 2% 2% 5% 2% 4% 4% 1% 1% 4% 1% 3% 5% 3% 4% 4% 3% 3% 3% 3% 0.20% 0.40% 0.7% 0 Completed Tx Discontinued Tx Summary 3HP regimen is being used successfully in the United States Initial programmatic experience is similar to treatment trial experiences High completions rates, notably in difficult populations Nausea is the most common reason for stopping treatment, but the majority of patients with nausea completed the regimen No deaths or severe organ damage detected Next Steps Treatment completion manuscript accepted by CID Draft manuscript on adverse events and association with medical conditions and medications completed Analysis in search of possible syndromes using market basket analysis almost completed Cost effectiveness analysis poster accepted at ATS conference 3HP standard regimen in Bureau of Prisons system 7
8 Other rifapentine based projects TB Trials Consortium (TBTC) Study 33 3HP SAT vs. DOT manuscript awaiting acceptance TBTC Study 35 pharmokinetic studies of dispersible rifapentine in children 3HP performance in other settings: Indian Health Services Veterans Administration Iqaluit community in the arctic circle! Collaboration between TBTC and TBESC for 6 week daily rifapentine clinical trial INH RPT Post implementation Workgroup Naveen Patil, Leonard Mukasa Rose Sales Mike Holcombe, Risa Webb Shea Rabley Jon Warkentin Jane Moore Ann Davis, Carla Chee Mike Arbisi Dick Brostrom, Derrick Felix Diana Fortune, Marco Burgos Dean Tsukiyama, Deb Sodt Neha Shah, Charlie Crane, Julie Higashi, Marisa Moore, Kim Fields, Mark Lobato, Kelley Bemis Maria Galves Garrett Hunt Phil Griffin Krissie Guerguard, Dee Pritschet Acknowledgments Lorna Will Margaret Oxtoby Narita Masa Sara Burr, Sherri Wheeler Kevin Winthrop, Heidi Behm CDC Field Services and Evaluation Branch Amy Sandul Bunie Nwana Vern Green Gail Grant Mark Miner John Jereb, Sundari Mase, Terry Chorba Victor Balaban Vincent Fears, Regina Gore, Andy Heetderks, Dan Ruggiero, Dawn Tuckey, Awal Khan, Lakshmy Menon, Brandy Peterson, Judy Gibson Data Management and Surveillance Branch Jose Becerra Lon Gross Clinical Research Branch Andy Vernon Elsa Villarino Ruth Moro Andrey Borisov Stefan Goldberg Nigel Scott Surveillance, Epidemiology and Outbreak Branch Tom Navin Krista Powell Severe Adverse Events Severe Adverse Events (SAE): any patient who was hospitalized or died while receiving 3HP 34 hospitalizations reported, not necessarily attributed to 3HP 11 seen in the ED but not hospitalized No deaths No serious or permanent medical sequelae Hospitalizations investigated in coordination with national surveillance for LTBI SAE project under Krista Powell and Lilia Manangan 8
Ruth Moro M.D., M.P.H. Medical Epidemiologist. CDC, Division of Tuberculosis Elimination Clinical Research Branch Tuberculosis Trials Consortium
Factors Associated with Non-completion of Latent Tuberculosis Infection (LTBI) Treatment: Reasons other than Adverse Events (AE) The TB Trials Consortium PREVENT TB Study 26 Ruth Moro M.D., M.P.H. Medical
More informationDisclosures. Public Health Motivation 6/6/2012. The 12-Dose INH-Rifapentine Once-Weekly DOT Regimen: What Next?
The 12-Dose INH-Rifapentine Once-Weekly DOT Regimen: What Next? NTCA Conference June 14, 2012 John Jereb, FSEB, DTBE, CDC Special thanks to Christine Ho, Elsa Villarino, and Andrey Borisov The findings
More informationSharing the Care: Working Together on LTBI Treatment and Management Webinar. September 24, Curry International Tuberculosis Center
TB Infection Diagnostics and Treatment Neha Shah MD MPH Field Medical Officer Tuberculosis Control Branch California Department of Public Health Centers for Disease Control and Prevention 1 Curry International
More informationExperience with Pyrazinamide and Rifampin Regimens for Latent TB Infection
Experience with Pyrazinamide and Rifampin Regimens for Latent TB Infection Krista Powell, MD, MPH Co-Project Officer, National Surveillance for Severe Adverse Events Associated with LTBI Treatment Lead,
More informationScaling up LTBI Treatment with Short Course Regimens to Eliminate TB
August 2016 Scaling up LTBI Treatment with Short Course Regimens to Eliminate TB Carol Dukes Hamilton, MD, MHS Director, Scientific Affairs and Leader, TB Portfolio, FHI 360 Professor of Medicine, Duke
More informationScaling up LTBI Treatment with Short Course Regimens
April 2016 Scaling up LTBI Treatment with Short Course Regimens Carol Dukes Hamilton, MD, MHS Director, Scientific Affairs, FHI 360 Professor of Medicine, Duke University Disclosures past 12 months No
More information10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose
Disclosures Updates in Tuberculosis I have nothing to disclose Chris Keh, MD Assistant Clinical Professor, Division of Infectious Diseases, UCSF TB Controller, TB Prevention and Control Program, Population
More informationPediatric Tuberculosis in Los Angeles County: An Update
Pediatric Tuberculosis in Los Angeles County: An Update Julie Higashi, MD PhD Director, Tuberculosis Control Program March 2, 2019 0 Pediatricians will be the driving force of TB elimination in California
More informationTuberculosis Epidemiology
Tuberculosis Epidemiology TB CLINICAL INTENSIVE COURSE Curry International Tuberculosis Center October 18, 2017 Varsha Hampole, MPH Tuberculosis Control Branch California Department Of Public Health Outline
More informationThe Tip of the Iceberg: Addressing Latent Tuberculosis Infection to Accelerate Tuberculosis Elimination
Four Corners TB and HIV Conference November 3, 2015 Durango, CO The Tip of the Iceberg: Addressing Latent Tuberculosis Infection to Accelerate Tuberculosis Elimination Philip LoBue, MD National Center
More informationTB EPIDEMIOLOGY. Outline. Estimated Global TB Burden, TB epidemiology
TB EPIDEMIOLOGY TB Clinical Intensive Course Curry International Tuberculosis Center September 30, 2015 Varsha Nimbal, MPH Tuberculosis Control Branch California Department of Public Health 1 Outline TB
More informationBackground. The global burden of latent M. tuberculosis. More than 2 billion people infected
What s New in Treatment tof LTBI Alfred Lardizabal, MD November 17, 2011 Washington, D.C. Background The global burden of latent M. tuberculosis infection is enormous More than 2 billion people infected
More informationExpanding Latent Tuberculosis Infection Testing and Treatment to Accelerate Tuberculosis Elimination
IUATLD North American Region Conference February 24, 2017 Vancouver, BC Expanding Latent Tuberculosis Infection Testing and Treatment to Accelerate Tuberculosis Elimination Philip LoBue, MD National Center
More informationLTBI Videos-Treatment
LTBI Videos-Treatment This program is presented by the Global Tuberculosis Institute and is based on recommendations from the Centers for Disease Control and Prevention. This is the third in a series of
More informationJeffrey R. Starke, M.D. has the following disclosures to make:
AAP 2018 Red Book Tuberculosis: IGRAs and Treatment of TB Infection Jeffrey R. Starke, M.D. May 31, 2018 AAP 2018 Red Book Childhood Tuberculosis: IGRAs and Treatment of TB Infection May 31, 2018 WEBINAR
More informationDisclosures. Updates in TB for the PCP: Opportunities for Prevention. Objectives PART 1: WHY TEST? 4/14/2016. None
Disclosures Updates in TB for the PCP: Opportunities for Prevention None Pennan Barry, MD, MPH Chief, Surveillance and Epidemiology, California TB Control Branch Assistant Clinical Professor, Division
More informationContact Investigation and Prevention in the USA
Contact Investigation and Prevention in the USA George D. McSherry, MD Division of Infectious Disease Penn State Children s Hospital Pediatric Section TB Center of Excellence Rutgers Global Tuberculosis
More informationSubstance Abuse and Tuberculosis Springfield, IL April 27, 2011
5/6/2011 Substance Abuse and Tuberculosis Springfield, IL April 27, 2011 Epidemiology of Substance Abuse and Tuberculosis: Where is the Problem? Debra Stephens, RN, BSN, MPH April 27, 2011 Debra Stephens,
More informationTherapy for Latent Tuberculosis Infection
Screening and Treatment of LTBI in TB Control in the US Margarita Elsa Villarino MD MPH Division of TB Elimination, CDC April 14, 2004 TB Prevention and Control in the United States The fundamental strategies
More informationTuberculosis: Where Are We Now?
Tuberculosis: Where Are We Now? Amee Patrawalla MD MPH Rutgers - NJ Medical School Global TB Institute Rutgers, The State University of New Jersey Learning Objectives Understand the current epidemiologic
More informationThe American Experience with TB Elimination
Reaching the Goal of TB Elimination by 2035 March 3, 2015 The American Experience with TB Elimination John Jereb, M.D. Medical officer Division of Tuberculosis Elimination National Center for HIV/AIDS,
More informationThe role of ART and IPT in TB prevention: Latest updates
The role of ART and IPT in TB prevention: Latest updates Richard E. Chaisson, MD Center for Tuberculosis Research Johns Hopkins University Consortium to Respond Effectively To the AIDS-TB Epidemic (CREATE)
More informationNew Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents
New Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents Jeffrey R. Starke, M.D. Professor of Pediatrics Baylor College of Medicine [With great thanks to Andrea
More informationGeneral Session VI - Lee Reichman April 21, 2017
Culture of Collaboration 2017 National TB Conference April 21, 2017 Atlanta, GA Lee B. Reichman, MD, MPH Professor of Medicine, Senior Advisor Rutgers NJMS Global TB Institute Newark, NJ Rutgers, The State
More informationPreventing TB: Recent Research Results and Novel Short Course Therapy for LTBI
Preventing TB: Recent Research Results and Novel Short Course Therapy for LTBI Constance A. Benson, M.D. Professor of Medicine Director, UCSD AntiViral Research Unit PI, CD4 Collaborative HIV Clinical
More informationDiagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, TB Nurse Case Management September 12 14, 2017
Diagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has
More information6/2/2014. TB among Persons Experiencing Homelessness DEFINING THE PROBLEM. Overview. Sapna Bamrah Morris, MD
TB among Persons Experiencing Homelessness Sapna Bamrah Morris, MD June 11, 2014 National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of TB Elimination Overview Defining the problem
More informationFor more information, contact
For more information, contact Division of Tuberculosis Elimination National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Coordinating Center for Infectious Diseases Centers for Disease
More informationThe authors assessed drug susceptibility patterns
Drug Resistance Among Tuberculosis Patients, 1991 and 1992 New York City, CYNTHIA R. DRIVER, RN, MPH THOMAS R. FRIEDEN, MD, MPH ALAN B. BLOCH, MD, MPH IDA M. ONORATO, MD All the authors are with the Division
More informationThe Public Health Impact of TB in the Correctional System. Sarah Bur, RN, MPH Federal Bureau of Prisons Infection Prevention and Control Officer
The Public Health Impact of TB in the Correctional System Sarah Bur, RN, MPH Federal Bureau of Prisons Infection Prevention and Control Officer The Public Health Impact of TB in the Correctional System
More informationTUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of
TUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of Health and Mental Hygiene TODAY S PRESENTATION Epidemiology
More informationTuberculosis Elimination
Tuberculosis Elimination Where We ve Been, Where We re Going Mark Lobato, MD New England TB Consultant Division of Tuberculosis Elimination Centers for Disease Control and Prevention Disclosures / Disclaimer
More informationTreatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015
Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015 Tuberculosis Infection Diagnosis and Treatment April 7, 2015 El Paso, TX EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has
More informationGender Disparities in Viral Suppression and Antiretroviral Therapy Use by Racial and Ethnic Group Medical Monitoring Project,
Gender Disparities in Viral Suppression and Antiretroviral Therapy Use by Racial and Ethnic Group Medical Monitoring Project, 2009-2010 Linda Beer PhD, Christine L Mattson PhD, William Rodney Short MD,
More informationMoving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012
Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 LTBI and TB Disease Treatment Cara Christ, MD, MS May 8, 2012 Cara Christ, MD, MS has the following disclosures to make: No conflict
More informationTreatment of Latent TB Infection (LTBI)
Treatment of Latent TB Infection (LTBI) Mahesh C. Patel, MD June 14, 2017 2014 MFMER slide-1 Mahesh C. Patel, MD Associate Professor Treatment of LTBI Department of Internal Medicine, Division of Infectious
More informationTB in Prisons and Jails Albuquerque, New Mexico November 28, 2012
TB in Prisons and Jails Albuquerque, New Mexico November 28, 2012 Challenges of TB Treatment in Special Populations in Corrections Marcos Burgos, MD November 28, 2012 Marcos Burgos, MD has the following
More information5. HIV-positive individuals treated with INH should receive Pyridoxine (B6) 25 mg daily or 50 mg twice/thrice weekly on the same schedule as INH
V. TB and HIV/AIDS A. Standards of Treatment and Management The majority of TB treatment principles apply to persons with HIV/AIDS who require treatment for TB disease. The following points are either
More informationCDC's Tuberculosis Trials Consortium
CDC's Tuberculosis Trials Consortium Kayla Laserson, Andrew Vernon, Erin Bliven, Neil Schluger, William Burman, Fred Gordin, Tim Sterling, Carol Dukes Hamilton, Debra Benator, Donna Conwell, Nancy Dianis,
More informationTBTC research update: are we ready for 3 month treatment? 2009 TBTC Recompetition. NTCA presentation outline
TBTC research update: are we ready for 3 month treatment? Stefan Goldberg, MD Project officer, TBTC Studies 27, 28, 29 Tuberculosis Trials Consortium (TBTC) CDC Division of TB Elimination NTCA breakout
More information11/1/2017. Disclosures. Update In Tuberculosis, Indiana Outline/Objectives. Pathogenesis of M.tb Global/U.S. TB Burden, 2016
Disclosures Update In Tuberculosis, Indiana 2017 Bradley Allen, MD, PhD, FACP, FIDSA Indiana University School of Medicine Division of Infectious Diseases Roudebush VAMC Indianapolis Medical Consultant,
More informationANNUAL TUBERCULOSIS REPORT OREGON Oregon Health Authority Public Health Division TB Program November 2012
ANNUAL TUBERCULOSIS REPORT OREGON 211 Oregon Health Authority Public Health Division TB Program November 212 Page 2 Table of Contents Charts Chart 1 TB Incidence in the US and Oregon, 1985-211... page
More informationLatent TB Infection Treatment
Latent TB Infection Treatment Douglas B. Hornick, MD Pulmonologist w/ Infectious Attitude Division of Pulmonary/Critical Care/Occ Med UI Carver College of Medicine 2014 MFMER slide-1 Disclosures: None
More informationPlease distribute a copy of this information to each provider in your organization.
HEALTH ADVISORY TO: Physicians and other Healthcare Providers Please distribute a copy of this information to each provider in your organization. Questions regarding this information may be directed to
More informationTB Update: March 2012
TB Update: March 2012 David Schlossberg, MD, FACP Medical Director, TB Control Program Philadelphia Department of Public Health 1 TB Update: March 2012 IGRAs vs TST LTBI A New Regimen NAATs What is Their
More informationSubstance Abuse and Tuberculosis Springfield, IL April 27, 2011
Substance Abuse and Tuberculosis Springfield, IL April 27, 2011 Co-morbidities in Substance Abuse that Impact Managing TB Lisa Armitige, MD, PhD April 27, 2011 Lisa Armitige, MD, PhD has the following
More informationTuberculosis in Chicago 2006
Chicago Department of Public Health May 27 Communicable Disease Information Tuberculosis in Chicago 26 City of Chicago Richard M. Daley, Mayor Department of Public Health Terry Mason, MD, FACS Commissioner
More informationLatent TB Infection (LTBI) Strategies for Detection and Management
Latent TB Infection (LTBI) Strategies for Detection and Management Patrick T. Dowling MD,MPH Professor and Chair Dept of Family Medicine David Geffen School of Medicine at UCLA Pri-Med March 29 2014 Pdowling@mednet.ucla.edu
More informationScott Lindquist MD MPH Tuberculosis Medical Consultant Washington State DOH and Kitsap County Health Officer
Tuberculosis in the 21 st Century Scott Lindquist MD MPH Tuberculosis Medical Consultant Washington State DOH and Kitsap County Health Officer Feedback Poll In my opinion, the recent media coverage of
More informationState Of Tuberculosis Elimination in the United States, 2017
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention State Of Tuberculosis Elimination in the United States, 2017 Philip LoBue, MD Director, Division of Tuberculosis Elimination Congressional
More informationTB Outbreak Investigation in Fishery Workers, Maryland. Cassandra Althauser PHASE Internship Maryland Department of Health and Human Hygiene
TB Outbreak Investigation in Fishery Workers, Maryland Cassandra Althauser PHASE Internship Maryland Department of Health and Human Hygiene Airborne Transmission Tuberculosis Small droplet nuclei (
More informationTB trends and TB genotyping
Management of a TB Contact Investigation for Public Health Workers Albuquerque, NM October 1, 214 TB trends and TB genotyping Marcos Burgos MD October 1, 214 Marcos Burgos, MD has the following disclosures
More informationWeekly. August 8, 2003 / 52(31);
Weekly August 8, 2003 / 52(31);735-739 Update: Adverse Event Data and Revised American Thoracic Society/CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis
More informationTuberculosis in Chicago 2007
City of Chicago Communicable Disease Information Department of Public Health Richard M. Daley, Mayor May 2008 Terry Mason, MD, FACS, Commissioner www.cityofchicago.org/health/ West Side Center For Disease
More informationModeling LTBI What are the key issues to consider? Dr Dick Menzies, Montreal Chest Institute, McGill International TB Centre
Modeling LTBI What are the key issues to consider? Dr Dick Menzies, Montreal Chest Institute, McGill International TB Centre Overview The problem Treating active TB does not seem to be enough The solution:
More informationDrivers of TB Transmission
Drivers of TB Transmission David Dowdy, MD PhD National TB Conference Atlanta, GA April 20, 2017 Motivation Ending TB transmission in the US is necessary (but not sufficient) for TB elimination. We will
More informationAuthor s response to reviews
Author s response to reviews Title: Treatment Completion for Latent Tuberculosis Infection: A Retrospective Cohort Study Comparing 9 months of Isoniazid, 4 months of Rifampin and 3 months of Isoniazid
More informationCommunicable Diseases
Communicable Diseases Communicable diseases are ones that can be transmitted or spread from one person or species to another. 1 A multitude of different communicable diseases are currently reportable in
More informationLatent Tuberculosis Infection (LTBI) Questions and Answers for Health Care Providers
Latent Tuberculosis Infection (LTBI) Questions and Answers for Health Care Providers Who Should Be Screened for Latent Tuberculosis Infection (LTBI)?... 2 What tests are used to screen for LTBI?... 2 How
More informationLatent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016
Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016 Randy Culpepper, MD, MPH Deputy Heath Officer/Medical Director Frederick County Health Department March 16, 2016 2 No
More informationTB PREVENTION: TREATMENT OF LATENT TB INFECTION AND BCG VACCINATION
TB PREVENTION: TREATMENT OF LATENT TB INFECTION AND BCG VACCINATION Michelle Haas, M.D. Denver Metro Tuberculosis Program Denver Public Health DISCLOSURES No relevant financial relationships OBJECTIVES
More informationTreatment of Drug-Susceptible Tuberculosis
American Thoracic Society / Centers for Disease Control / Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis On behalf of the writing committee
More informationHIV as a Risk Factor for TB Henry Pacheco, MD November 13, 2008
Tuberculosis Updates for Clinicians San Antonio, Texas November 13, 2008 HIV as a Risk Factor for TB Henry Pacheco, MD November 13, 2008 HIV as a Risk Factor for TB Tuberculosis Update for the Clinician
More informationClinical Trials Lecture 4: Data analysis
Clinical Trials Lecture 4: Data analysis Dick Menzies, MD Respiratory Epidemiology and Clinical Research Unit Montreal Chest Institute TB Research methods course July 17, 2014 Lecture 4: Data analysis
More informationRevised Technical Instructions for Civil Surgeons. October 9, 2018
Revised Technical Instructions for Civil Surgeons October 9, 2018 Speakers Joanna Regan Centers for Disease Control and Prevention Shereen Katrak California Department of Public Health Pennan Barry California
More informationTargeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University
Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University Tuberculosis Estimates USA World Infection 15,000,000 2,000,000,000
More informationTuberculosis Populations at Risk
Tuberculosis Populations at Risk One-third of the world is infected with TB, an average of one new infection per second Two million people died from tuberculosis in 2010, 1 every 20 seconds TB is the leading
More informationManagement of Patients with TB Infection Catalina Navarro, RN, BSN April 7, 2015
Management of Patients with TB Infection Catalina Navarro, RN, BSN April 7, 2015 Tuberculosis Infection Diagnosis and Treatment April 7, 2015 El Paso, TX EXCELLENCE EXPERTISE INNOVATION Catalina Navarro,
More informationTuberculosis: A Provider s Guide to
Tuberculosis: A Provider s Guide to Diagnosis and Treatment of Active Tuberculosis (TB) Disease and Screening and Treatment of Latent Tuberculosis Infection (LTBI) Alameda County Health Care Services Agency
More informationChapter 5 Treatment for Latent Tuberculosis Infection
Chapter 5 Treatment for Latent Tuberculosis Infection Table of Contents Chapter Objectives.... 109 Introduction.... 111 Candidates for the Treatment of LTBI... 112 LTBI Treatment Regimens.... 118 LTBI
More informationTreatment of Tuberculosis, 2017
Treatment of Tuberculosis, 2017 Charles L. Daley, MD National Jewish Health University of Colorado Health Sciences Center Treatment of Tuberculosis Disclosures Advisory Board Horizon, Johnson and Johnson,
More informationTuberculosis Intensive November 17 20, 2015 San Antonio, TX
Treatment of Tuberculosis Elizabeth S. Guy, MD November 17, 2015 Tuberculosis Intensive November 17 20, 2015 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Elizabeth S. Guy, MD has the following disclosures
More information2016 Annual Tuberculosis Report For Fresno County
206 Annual Tuberculosis Report For Fresno County Cases Rate per 00,000 people 206 Tuberculosis Annual Report Fresno County Department of Public Health (FCDPH) Tuberculosis Control Program Tuberculosis
More informationTreatment of Tuberculosis
Treatment of Tuberculosis Marcos Burgos, MD April 5, 2016 TB Intensive April 5 8, 2016 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Marcos Burgos, MD has the following disclosures to make: No conflict
More informationACTIVE TUBERCULOSIS IN MACOMB COUNTY, A Review of TB Program Data,
ACTIVE TUBERCULOSIS IN MACOMB COUNTY, 1996-2010 A Review of TB Program Data, 1996-2010 Prepared by: Janice M. Chang, MBBS, MPH Division Director, Health Promotion and Disease Control Macomb County Health
More informationTrends in HIV Incidence and Prevalence in the United States
Trends in HIV Incidence and Prevalence in the United States Irene Hall, PhD, FACE 7th International Workshop on HIV Transmission Washington, DC, July 20, 2012 National Center for HIV/AIDS, Viral Hepatitis,
More informationDisclosures. Current Issues and Controversies in Child and Adolescent Tuberculosis 02/24/2016. NSTC 2016 Annual Meeting
Current Issues and Controversies in Child and Adolescent Tuberculosis Jeffrey R. Starke, M.D. Professor of Pediatrics Baylor College of Medicine [With great thanks to Andrea Cruz, M.D.] Disclosures Dr.
More informationThird Annual World TB Day Symposium: Showcasing Clinical and Epidemiologic Studies on TB at the UW. March 24, 2016
Third Annual World TB Day Symposium: Showcasing Clinical and Epidemiologic Studies on TB at the UW March 24, 2016 World TB Day Symposium Planning Committee David Horne, MD, MPH Jessica Matthews, MPH Alexandra
More informationBetween 1995 and 2010, medical consultants for the
SPECIAL ARTICLE Translating Tuberculosis Research into Practice: Collaboration Between Academic Researchers and Public Health Departments in North Carolina David P. Holland, Emily J. Hecker, Ann W. Mosher,
More informationDisclosures. Outline. No disclosures or conflicts of interest to report. Special LTBI situations. H t it d id ff t
Selected Topics in LTBI June 2, 2015 Bijan Ghassemieh, MD Senior Fellow UW Division of Pulmonary/Critical Care Disclosures No disclosures or conflicts of interest to report Outline Special LTBI situations
More informationTuberculosis and Biologic Therapies: Risk and Prevention
Tuberculosis and Biologic Therapies: Risk and Prevention Kevin L. Winthrop, MD, MPH Associate Professor, Divisions of Infectious Diseases, Public Health and Preventive Medicine Oregon Health & Science
More informationThe Role of Rifampin for the Treatment of Latent TB Infection. Introduction. Introduction
The Role of Rifampin for the Treatment of Latent TB Infection March 26, 2008 Alfred A. Lardizabal, MD Associate Professor of Medicine New Jersey Medical School Global Tuberculosis institute Treatment of
More informationCommunicable Disease Control Manual Chapter 4: Tuberculosis. Assessment and Follow-Up of TB Contacts
Provincial TB Services 655 West 12th Avenue Vancouver, BC V5Z 4R4 www.bccdc.ca Communicable Disease Control Manual Assessment and Follow-Up of TB July, 2018 Page 1 TABLE OF CONTENTS 8.0 ASSESSMENT AND
More informationLatent tuberculosis infection
EXECUTIVE SUMMARY Latent tuberculosis infection Updated and consolidated guidelines for programmatic management Executive summary Latent tuberculosis infection (LTBI) is defined as a state of persistent
More informationDiversity Data Snapshots March 2014 Edition
Diversity Data Snapshots March 2014 Edition Diversity Policy and Programs CDC Health Disparities and Inequalities Report United States, 2013 CDC Health Disparities and Inequalities Report United States,
More informationHaley Blake Sage Nagai, MPH. Disease Investigation and Intervention Specialists Tuberculosis Treatment and Control Clinic
Haley Blake Sage Nagai, MPH Disease Investigation and Intervention Specialists Tuberculosis Treatment and Control Clinic Discuss the prevalence of tuberculosis in Clark County Describe factors influencing
More informationANNEXURE A: EXPLANATORY NOTES ON THE DMR 164 REPORTING ON HIV AND TB FORM
ANNEXURE A: EXPLANATORY NOTES ON THE DMR 164 REPORTING ON HIV AND TB FORM The form and content of the explanatory note is to: Inform those responsible for completing the DMR 164 Reporting Form - as to
More informationInfectious Diseases New York City Department of Health and Mental Hygiene, Division of Disease Control (Bureau of HIV/AIDS Prevention and Control)
Infectious Diseases New York City Department of Health and Mental Hygiene, Division of Disease Control (Bureau of HIV/AIDS Prevention and Control) Queens, New York Assignment Description The host site
More informationDisclosure Informa0on Western Occupa0onal Health Conference 2012
Infec&ous Disease: Guidelines, Updates & Implementa&on in the Health Care Se=ng James Watt, MD, MPH Chief, Division of Communicable Disease Control Center for Infectious Diseases California Department
More informationTuberculosis in Alameda County, 2012
Tuberculosis in Alameda County, 212 Alameda County Public Health Department Tuberculosis Overview Tuberculosis (TB) is a preventable and curable disease that remains one of the leading causes of death
More informationThe Epidemiology of Tuberculosis in Minnesota,
The Epidemiology of Tuberculosis in Minnesota, 2011 2015 Minnesota Department of Health Tuberculosis Prevention and Control Program (651) 201-5414 Tuberculosis surveillance data for Minnesota are available
More informationObjectives. 3HP and Flu Syndrome What is the Underlying Mechanism? Case #1 3/23/2016. Christina T. Fiske, MD MPH March 30, 2016
Objectives 3HP and Flu Syndrome What is the Underlying Mechanism? Christina T. Fiske, MD MPH March 30, 2016 Illustrate the side effect of 3HP flu like syndrome after its initiation to raise awareness in
More informationClinical and Behavioral Characteristics of HIV-infected Young Adults in Care in the United States
Clinical and Behavioral Characteristics of HIV-infected Young Adults in Care in the United States Linda Beer, PhD, Christine L. Mattson, PhD, Joseph Prejean, PhD, and Luke Shouse, MD 10 th International
More informationACCESS TO MEDICINES. Update on tuberculosis field activities
ACCESS TO MEDICINES Update on tuberculosis field activities Update on clinical activities 1/3 Latent TB Prevent study (S26) main study (8053 patients) PK substudy construction of a POPPK model Paediatric
More informationTreatment of latent tuberculosis infection: An update
INVITED REVIEW SERIES: TUBERCULOSIS SERIES EDITORS: WING WAI YEW, GIOVANNI B. MIGLIORI, CHRISTOPH LANGE Treatment of latent tuberculosis infection: An update PHILIP LOBUE 1 AND DICK MENZIES 2 1 Division
More informationTUBERCULOSIS. Presented By: Public Health Madison & Dane County
TUBERCULOSIS Presented By: Public Health Madison & Dane County What is Tuberculosis? Tuberculosis, or TB, is a disease caused by a bacteria called Mycobacterium tuberculosis. The bacteria can attack any
More informationFactors Associated With Non-completion of Latent TB Infection Treatment in the Homeless Population Enrolled in the PREVENT TB Trial
Georgia State University ScholarWorks @ Georgia State University Public Health Theses School of Public Health Winter 1-8-2016 Factors Associated With n-completion of Latent TB Infection Treatment in the
More informationIsoniazid Preventive Therapy (IPT)
Isoniazid Preventive Therapy (IPT) Josefina Cadorna-Carlos, M.D. Professor of Pediatrics U E R M M M C Objectives 1. Define IPT. 2. Discuss the indications for IPT. 3. Present RCT s for IPT (6H vs 9H).
More informationU.S. Counties Vulnerability to Rapid Dissemination of HIV/HCV Infections Among People Who Inject Drugs
U.S. Counties Vulnerability to Rapid Dissemination of HIV/HCV Infections Among People Who Inject Drugs Michelle Van Handel, MPH Health Scientist National Center for HIV/AIDS, Viral Hepatitis, STDs and
More informationState of the State in TB Control
State of the State in TB Control Jason Stout, MD, MHS Wake County TB Medical Consultant NC TB Medical Director Division of Infectious Diseases, Duke University Medical Center Disclosures-Funding NIH (grant)
More information